Loading…
Brand of Phenylephrine
GALPHARM ALL IN ONE COLD AND FLU LIQUID, NUMARK ALL IN ONE COLD AND FLU LIQUID is a brand name for Phenylephrine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For the short term symptomatic relief of the symptoms of colds and influenza, including aches and pains, headache, nasal congestion, tickly sore throat and chesty coughs.
Verbatim from this product's MHRA label. Tap a section to expand.
For oral administration.
Adults and adolescents 16 years and over:
One 20ml dose (four 5ml spoonfuls) up to 4 times a day as required. The dose must not be repeated more frequently than every 4-6 hours. Maximum of 4 doses in any 24 hours. Not recommended for children under 16 years of age.
Elderly patients:
Elderly patients, especially those who are frail or immobile, may require a reduced dose or frequency of dosing.
Renal impairment:
Patients who have been diagnosed with kidney impairment must seek medical advice before taking this medication. It is recommended, when giving paracetamol to patients with renal failure, to reduce the dose and to increase the minimum interval between each administration to at least 6 hours.
4).
Hepatic impairment:
Patients who have been diagnosed with hepatic impairment or Gilbert’s Syndrome must seek medical advice before taking this medication. 4). 9). Minimum dosing interval: 4 hours. If pain or fever persist for more than 3 days or get worse, or if any other symptoms occur, treatment should be discontinued and a physician consulted.
Adverse reactions reported from extensive postmarketing experience are tabulated below by System Organ Class and frequency. The following convention has been utilised for the classification of undesirable effects: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, 246 <1/100), rare (≥1/10,000, <1/1000), very rare (<1/10,000), not known (cannot be estimate from available data).
Respiratory, thoracic and mediastinal disorders Bronchospasm in patients sensitive to aspirin and other NSAIDs Not Known Hepatobiliary disorders Hepatic dysfunction Not known Cutaneous hypersensitivity reactions including skin rashes, pruritus, sweating, purpura, urticaria and angioedema Not Known Skin and subcutaneous tissue disorders Very rare case of serious skin reactions have been reported.
Very rare Paracetamol:
System Organ class Undesirable effect Frequency Blood and lymphatic system disorders Thrombocytopaenia, Agranulocytosis Not known Anaphylaxis Not known Immune system disorders Allergies (not including angioedema) Not known Renal and urinary disorders Sterile pyuria (cloudy urine) Not known Gastrointestinal disorders Acute pancreatitis, associated with the ingestion of above normal dosage Not known Metabolism and nutrition disorders High anion gap metabolic acidosis Not known Phenylephrine: System Organ Class Undesirable effect Frequency Immune system disorders Hypersensitivity reactions-including that crosssensitivity may occur with other sympathomimetics Not known Psychiatric disorders Nervousness, insomnia, irritability, anxiety, restlessness, excitability, hallucinations and paranoid delusions Not Known Nervous system disorders Headache, dizziness Not Known Cardiac disorders Increased blood pressure, other cardiac dysrhythmias Not Known Vascular disorders Hypertension Not Known Gastrointestinal disorders Nausea, vomiting, diarrhoea Not Known Skin and subcutaneous tissue disorders Skin reactions including rash Not Known Renal and urinary disorders urinary retention Not Known Adverse reactions identified during post-marketing use are listed below.
Underlying liver disease increases the risk of paracetamol related liver damage. The hazard of overdose is greater in those with non-cirrhotic alcoholic liver disease. g. amitryptilin) as this may increase the risk of cardiovascular side effects.
Precaution should be observed in patients with asthma who are sensitive to acetylsalicylic acid, since mild bronchospasms are reported in association with paracetamol(cross-reaction). Do not take with other cold or decongestant medicines or any other paracetamol containing products.
g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin. If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoring is recommended.
The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors. Immediate medical advice should be sought in the event of an overdose, even if you feel well, because of the risk of delayed, serious liver damage.
Patients who have been diagnosed with liver or kidney impairment must seek medical advice before taking this medication. The product should be administered only with particular caution under the following circumstances: - Chronic alcoholism - Gilbert’s Syndrome (familial non-haemolytic jaundice) - Concomitant treatment with medicinal products affecting hepatic function - Glucose-6-phosphate dehydrogenase deficiency - Haemolytic anaemia - Glutathione deficiency - Dehydration - Chronic malnutrition - The elderly, adults and adolescents weighing less than 50kg - Urinary retention - Raynaud's syndrome) If any of the following occur, the product should be stopped: • Hallucinations.
• Restlessness. • Sleep disturbances. Do not exceed the stated dose. This product is not suitable for long term use. If symptoms persist consult your doctor. 286g of Sorbitol. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
1. • Cardiovascular disease • Hypertension • Hyperthyroidism • Diabetes mellitus • Pheochromocytoma • Monoamine oxidase inhibitors (MAOIs), within 14 days of stopping treatment, see section
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Phenylephrine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
As these reactions are reported voluntarily from a population of uncertain size, the frequency of these reactions is unknown but considered likely to be rare or very rare. System Organ class Undesirable effect Frequency Eye disorders Mydriasis, acute angle closure glaucoma, most likely to occur in those with closed angle glaucoma Not Known Cardiac disorders Tachycardia, palpitations Not Known Immune system disorders Hypersensitivity, urticaria, allergic dermatitis Not Known Skin and subcutaneous disorders Rash Not Known Renal and urinary disorders Dysuria, urinary retention, most likely to occur in those with bladder outlet obstruction, such as prostatic hypertrophy.
g. rash, urticaria) Not Known Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisations of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard.
This product may have a mild laxative effect. This product contains 19% (v/v) ethanol. Each dose contains up to 3g of ethanol (alcohol) equivalent to 32ml of wine or 76ml of beer. Harmful for those suffering from alcoholism. To be taken into account in pregnant or breast feeding women, children and high-risk groups such as patients with liver disease, epilepsy.
The amount of alcohol in this medicinal product may alter the effects of other medicines. The amount of alcohol in this medicinal product may impair your ability to drive or use machines.
+4 more